Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

NCT04839991 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced and/or Metastatic Solid Tumours

Interventions

DRUG: CB307

Sponsor

Crescendo Biologics Ltd.